[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Algernon Health Inc (AGN.CN)

Algernon Health Inc (AGN.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Algernon Health Inc 601 West Broadway Suite 400 Vancouver BC V5Z 4C2 CAN

P: 604-646-1553

Sector:

N/A

INDUSTRY GROUPING:

N/A

Description:

Algernon Health Inc is a clinical-stage pharmaceutical development company focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), and stroke, including a program utilizing N,N-Dimethyltryptamine (DMT). Drug re-purposing (also known as re-profiling, re-tasking, or therapeutic switching) involves applying approved drugs and compounds to treat diseases. In addition, the Company is entering the Alzheimer's disease (AD) diagnostic market segment and plans to establish a network of dedicated neuroimaging medical clinics in North America, utilizing FDA-cleared, brain-specific PET scanners to focus on early-stage detection of the disease.

Key Statistics

Overview:

Market Capitalization, $K 2,438
Shares Outstanding, K 5,418
% of Institutional Shareholders 0.00%

Financials:

Annual Sales, $ 0 K
Annual Net Income, $ -1,717 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -597 K

Growth:

1-Year Return -47.06%
3-Year Return -82.00%
5-Year Return -98.91%
5-Year Revenue Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.20 on 01/29/26
Next Earnings Date N/A
Earnings Per Share ttm -0.70
EPS Growth vs. Prev Year 133.52%
Dividend Payout Ratio 0.00%
Most Recent Split 1-10 on 04/21/26

AGN.CN Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -118.76%
Return-on-Assets % -45.04%
Profit Margin % 0.00%
Debt/Equity N/A
Price/Sales N/A
Price/Book 1.66
Book Value/Share 0.27
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.